UAMY reports Wednesday with one of the tightest borrow markets in its history — and a short base large enough to matter.
The lending setup is the defining feature of this earnings. Availability has been effectively zero for weeks, meaning every share in the lending pool is currently lent out. That condition has persisted almost without interruption since late June. Short interest sits at 21.3% of the free float — a genuinely elevated reading — and has fallen roughly 13% over the past month from a peak above 24%, suggesting some shorts have already covered into the recent run. The stock gained 7.5% on the week heading into the print, closing at $6.58. Cost to borrow, while still positive at 1.3%, has eased considerably from the 2.2% levels seen in early July, a sign that covering activity has loosened the fee pressure even if availability remains absent.
Options positioning paints a different picture: call-side dominance. The put/call ratio is running at just 0.22, well below the 52-week high of 0.73 and slightly below its recent average, suggesting traders have been buying calls rather than hedging with puts. That is an unusually bullish lean for a stock where one in five freely tradeable shares is sold short. Peers in the critical-minerals space have moved sharply higher on the week — surged 24.7%, gained 22.2%, and rose 20.1% — which explains some of the call interest, as sector momentum has been strong. UAMY's own 7.5% weekly gain looks modest by comparison, leaving room in either direction.
The bull and bear cases here centre almost entirely on antimony pricing and operational execution. Antimony has moved from under $6 per pound to nearly $29 — a near-fivefold move — and bulls point to management's guidance of $125 million in 2026 revenue as the target the print is being measured against. Domestic supply projects in Alaska and Montana are the medium-term margin story. Bears counter that the company posted a $3.9 million net loss despite that price tailwind, driven in part by share-based compensation, and that an EV/EBITDA near 34x leaves little room for operational disappointment. The only recent analyst coverage from HC Wainwright maintained a Buy with a $11.75 target — well above the current $6.58 price — though that note dates to May and does not constitute fresh conviction. The ORTEX short score is elevated at 72.2, placing UAMY in the bottom 1% of the universe on that measure.
Institutional activity adds a wrinkle: Van Eck Associates entered with a full position of 10.4 million shares last reported in July, while State Street added 3.3 million shares in the same period. BlackRock also added 1.5 million shares. That trio of additions — all critical-minerals or commodity-focused — implies the ownership base is tilting toward investors who want the sector exposure regardless of quarterly noise. On the insider side, the CFO sold nearly $1 million worth of shares in June at $9.75, well above the current price, while a director made a token purchase of $93,000. The net picture is one of insiders reducing at higher levels as institutions build from below.
Wednesday's print will test whether UAMY's revenue trajectory is tracking toward that $125 million annual target — and whether margins are improving fast enough to justify a valuation that already prices in a great deal of antimony price strength.
See the live data behind this article on ORTEX.
Open UAMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
